NHS mandates AI-powered analysis to treat coronary heart disease

HeartFlow has announced that the National Health Service England (NHSE) and NHS Improvement have mandated that English hospitals adopt the AI-powered HeartFlow FFRct Analysis to fight coronary heart disease (CHD). The HeartFlow Analysis has been selected as one of the innovations supported by NHSE's new MedTech Funding Mandate. The Mandate, which will begin 1st April 2021, aims to provide innovative medical devices and digital products to NHSE patients faster, and is a key policy in helping to improve patient care and reduce costs for the public health service. The Mandate includes the option to extend funding for up to an additional three years through 31 March 2024. HeartFlow has also received extended funding through NHSE's Innovation and Technology Payment Programme (ITP) for a third year.